|
BRWD3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.6403990932854E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.86369999935587E-08 |
| Normal-vs-Stage2 |
6.07609999980774E-07 |
| Normal-vs-Stage3 |
8.93179974426062E-11 |
| Normal-vs-Stage4 |
1.80000000460367E-08 |
| Stage1-vs-Stage2 |
5.405000E-01 |
| Stage1-vs-Stage3 |
8.670300E-02 |
| Stage1-vs-Stage4 |
1.482380E-01 |
| Stage2-vs-Stage3 |
5.095400E-01 |
| Stage2-vs-Stage4 |
5.931000E-01 |
| Stage3-vs-Stage4 |
9.334400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.63959981544804E-10 |
| Normal-vs-AfricanAmerican |
5.061200E-03 |
| Normal-vs-Asian |
2.11210000045092E-07 |
| Caucasian-vs-AfricanAmerican |
2.478200E-01 |
| Caucasian-vs-Asian |
6.535400E-01 |
| AfricanAmerican-vs-Asian |
1.554790E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.23520091324758E-11 |
| Normal-vs-Female |
1.36529998417956E-09 |
| Male-vs-Female |
2.104200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.01449999956316E-07 |
| Normal-vs-Age(41-60Yrs) |
1.79600001537494E-09 |
| Normal-vs-Age(61-80Yrs) |
1.43940004360132E-09 |
| Normal-vs-Age(81-100Yrs) |
1.183420E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.184200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.857160E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.231700E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.151200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.187400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.913020E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.000270E-03 |
| Classical-VS-Follicular |
2.147400E-01 |
| Classical-VS-Other |
1.276970E-01 |
| Classical-VS-Normal |
4.88740004023214E-09 |
| Tall-VS-Follicular |
1.021360E-01 |
| Tall-VS-Other |
7.207200E-01 |
| Tall-VS-Normal |
1.80840009633698E-10 |
| Follicular-VS-Other |
1.429210E-01 |
| Follicular-VS-Normal |
2.06489999987625E-07 |
| Other-VS-Normal |
5.769800E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.28870034035822E-10 |
| Normal-vs-N1 |
1.77311999999263E-05 |
| N0-vs-N1 |
6.863800E-01 |
|
|
